Abzena has entered into a master service agreement with NYU Langone Health. The agreement, for protein engineering and drug discovery services, will help NYU Langone’s drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics.
The first project under this master agreement centers around the development of a novel biopharmaceutical being developed by NYU OTA for the treatment of severe autoimmune disease. Abzena will provide integrated development support from its bioassay, immunology and protein engineering groups.
NYU School of Medicine is one of the USA’s top-ranked medical schools. An integral part of NYU Langone Health, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research, and direct patient care.
“It’s fantastic that our expertise and integrated offering across our biology group is being used in the development of another promising treatment,” Dr. Campbell Bunce, SVP, Scientific Operations, Abzena said. “This agreement represents another example of Abzena supporting exciting drug candidates from academic groups, utilizing not just our services but also our significant biologics know-how.”